INVA - テラバンス （Innoviva Inc.）

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022. Gross royalty revenues of $54.7 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2022 included royalties of $44.3 million from global net sales of RELVAR®/BREO® ELLIPTA® and royalties of $10.4 million from global

Pfizer Inc. could outperform with consistent dividend and revenue growth. Regeneron Pharmaceuticals Inc. has a high P/E with a low upside but value could increase on continued revenue growth. Innoviva Inc. started the year heavily down but strong revenue gains could offset projected losses. Exelixis Inc. is near its 52-week bottom but a furtive P/E […]

I think the most recent financial results of Innoviva are a mixed bag at best: revenue is down, profits are up. Click here to read my analysis of INVA stock.

The U.S. Food and Drug Administration ((FDA)) granted priority review to Innoviva''s (INVA) application seeking approval of SUL-DUR to treat infections caused by…

Innoviva press release (NASDAQ:INVA): Q3 GAAP EPS of $2.80.Revenue of $67.26M (-31.3% Y/Y).

I think the problem of higher revenues and lower profits lingers, and I think there''s risk in the recent acquisitions. Read more about INVA here.

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time. A live webcast of the fireside chat can be accessed under “Events & Presentation

Innoviva Inc. (NASDAQ:INVA) concluded the trading at $13.08 on Friday, September 02 with a rise of 0.54% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $13.01 and 5Y monthly beta was reading 0.50 with its price kept floating in the range … Innoviva Inc. (INVA) Worth Considering For The Next Few Weeks Read More »

https://www.investing.com/news/pro/innoviva-completes-purchase-of-la-jolla-pharmaceutical-432SI-2877480

Pulled from Benzinga Pro data, Innoviva (NASDAQ: INVA ) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2. Innoviva earned $37.86 million, and sales totaled $90.06 million in Q1. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com

Pulled from Benzinga Pro data, Innoviva (NASDAQ: INVA ) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2. Innoviva earned $37.86 million, and sales totaled $90.06 million in Q1. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com

Innoviva (NASDAQ: INVA ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Innoviva missed estimated earnings by 84.85%, reporting an EPS … Full story available on Benzinga.com

Innoviva press release (INVA): Q2 GAAP EPS of $0.05.Revenue of $108.22M (+7.4% Y/Y).Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same…

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022. Gross royalty revenues of $111.7 million from Glaxo Group Limited (“GSK”) for the second quarter of 2022 included royalties of $59.3 million from global net sal

Shares of Innoviva (INVA) fell as much as 2.4% to $14.37 in Wednesday trading after Goldman Sachs initiated the company with a neutral rating.Goldman Sachs analyst Chris Shibutani gave…